Company / Shareholders' Equity
Praxis Precision Medicines, Inc. Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$878.1M
FY2025
5-year range
$69.7M / $878.1M
FY2021-FY2025
Trend
+97.1%
vs FY2024
Sector context
#53 of 213
Health Care
What the data says
Praxis Precision Medicines, Inc.'s shareholders' equity of $878M is higher than 75% of companies in the Health Care sector (FY2025). Improved from $70M to $878M over the past 2 years.
Based on SEC 10-K filings.
$878M in FY2025 with a 5-year CAGR of +25.0%. Top quartile in the Health Care sector.
Improved from $70M to $878M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +126.0%
- 5-Year CAGR
- +25.0%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 213This company $878.1M Sector average $2.5B
▼
-65.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +25.0%, indicating consistent growth.
- In FY2025, shareholders' equity increased 97.1% year-over-year.
- Ranks #53 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 4.48 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $878.1M | +97.1% |
| FY2024 | $445.4M | +539.4% |
| FY2023 | $69.7M | -8.5% |
| FY2022 | $76.1M | -69.7% |
| FY2021 | $250.8M | -12.7% |
| FY2020 | $287.5M | +454.9% |
| FY2019 | -$81.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026